Present medical management of Barrett's oesophagus

Digestive and Liver Disease

Volumn 33, Issue 3, 2001, Pages 278-283

  Plevris, J N ^a   Heading, R C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Barrett's oesophagus; High grade dysplasia; Photodynamic therapy; Surveillance endoscopy

Indexed keywords

AMINOLEVULINIC ACID; CYCLOOXYGENASE 2 INHIBITOR; HEMATOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PORFIRMER SODIUM; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; EARLY CANCER; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; ESOPHAGUS SURGERY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; LASER SURGERY; MALE; PALLIATIVE THERAPY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; YAG LASER;

EID: 0035003157     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1590-8658(01)80719-2     Document Type: Article

References (64)

1. Shields HM, Sawhney RA, Zwas F, Boch JA, Kim S, Goran D, et al. Scanning electron microscopy of the human esophagus: application to Barrett's esophagus, a precancerous lesion. Microsc Res Tech 1995:31:248-56.
2. Levine DS.Barrett's esophagus. Current Opinion in Gastroenterology 1996;12:385-91.
3. Winters C, Spurling TJ, Chobanian SJ, Curtis D, Esposito RL, Hacker JF, et al. Barrett's oesophagus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
4. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar lined (Barrett's) oesophagus: Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
5. Corder AP, Jones RH, Millward Sadler GH, Daniels P, Johnson CD. Heartburn, oesophagitis and Barrett's oesophagus in self-medicating patients in general practice. Br J Clin Pract 1996;50:245-8.
6. Wang KK. Barrett's esophagus: current and future management. Compr Ther 1994;20:36-43.
7. Wright TA, Gray MR, Morris AI, Gilmore IT, Ellis A, Smart HL, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
8. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol 1980;33:801-10.
9. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastroesophageal junction. Lancet 1994;344:1533-6.
10. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996;110:614-21.
11. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barren's esophagus. Gastroenterology 1995;109:1541-6.
12. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20.
13. Howard PJ, Heading RC. Epidemiology of gastro-oesophageal reflux disease. World J Surg 1992;16:288-93.
14. Kauer WKH, Perers JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone: the need for surgical therapy re-emphasized. Ann Surg 1995;222:525-3.
15. Caldwell MTP, Lawlor P, Byrne PJ, Walsh TN, Hennessy TPJ. Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg 1995;82:657-60.
16. Vaezi MF, Richter JE. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's oesophagus. Surgery 1995;117:699-704.
17. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and the esophagogastric junction. Gastroenterology 1993;104:510-3.
18. McFarlane GJ, Boyle P. The epidemiology of esophageal cancer in UK and other European countries. J R Soc Med 1994;78:334-7.
19. Cameron AJ. Barrett's esophagus: Does the incidence of adenocarcinoma matter? Am J Gastroenterol 1997;92;193-4.
20. Lagergren J, Bergstrom R, Lindgren A, Nuren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
21. Kim SL, Waring JP, Spechler SJ, Sampliner RE, Doos WG, Krol WF, et al. The Department of Veterans Affairs Gastroesophageal Reflux study group. Diagnostic inconsistencies in Barrett's oesophagus. Gastroenterology 1994;107:945-9.
22. Hassall E. Childhood oesophagus under the microscope. Am J Surg 1994;167:287-90.
23. Geisenger KR. Endoscopic biopsies and cytologic brushings of the oesophagus are diagnostically complementary. Am J Clin Pathol 1995;103:295-9.
24. Srivastava AK, Vanagunas A, Kamel P, Cooper R. Endoscopic ultrasound in the evaluation of Barrett's oesophagus: a preliminary report. Am J Gastroenterol 1994;89:2192-5.
25. Falk GW, Catalano MF, Sivak Jr MV, Rice TW, Van Dam J. Endosonography in the evaluation of patients with Barrett's oesopgagus and high-grade dysplasia. Gastrointest Endosc 1994;40:207-12.
26. Stevens PD, Lightdale CJ, Green PHR, Siegel LM, Garcia-Carrasquillo RJ, Rotterdam H. Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett's oesophagus. Gastrointest Endosc 1994;40:747-9.
27. Panjehpour M, Overholt BF, Dinh TV, Haggit RC, Edwards DH, Buckley FP. Endoscopic fluorescence detection of high grade dysplasia in Barrett's oesophagus. Gastroenterology 1996;111:93-111.
28. Krishnadeth KK, Van Blankestein M, Tilanus HW. Prognostic value of p53 in Barrett's oesophagus. Eur J Gastroenterol Hepatol 1995;7:81-4.
29. Swift A, Risk JM, Kingsnorth AN, Wright TA, Myskow M, Field JK. Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. Br J Cancer 1995;71:995-8.
30. Robaszkiewicz M, Nousbaum JB, Cauvin JM, Robert FX, Volant A, Gouerou H. Barrett's oesophagus and dysplastic lesions. Gastroenterol Int 1994;7:S179-87.
31. Jankowski J, Hopwood D, Hurst H, Wright N, Molecular surveillance of Barrett's oesophagus and putative strategies for genetic therapy. Diseases of the Oesophagus 1995;8:113-8.
32. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplatic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
33. Dent J, Brun J, Fendrick AM, Fennerty MB, Jonssens J, Kahnifas RJ, et al. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16.
34. Conference de Consensus Franco-Belge. Reflux Gastro-Oesophagien de L'Adulte. Gastroenterol Clin Biol 1999;23:S1-320.
35. van Den Burgh A, Dees J, Hop WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:113-8.
36. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's oesophagus. Am J Gastroenterol 1994;89:670-80.
37. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
38. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
39. Dent J. Approaches to oesophageal columnar metaplasia (Barrett's oesophagus) Scand J Gastroenterol 1989;24:S60-6.
40. Pera M, Traskek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's oesophagus with high grade dysplasia: an indication to oesophagectomy? Ann Thorac Surg 1992;54:199-204.
41. Provenzale D, Wong JB. Esophagectomy for high grade dysplasia in patients with Barrett's esophagus; Are there cost-effective alternatives? Gastroenterology 1996;110:A34.
42. Levine DS, Haggitt RC, Irvine S, Reid BJ. Natural history of high-grade dysplasia in Barrett's oesophagus. Gastroenterology 1996;110:A550.
43. Gray MR, Donnely RJ, Kingsnorth AN. The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. Gut 1993;34:727-31.
44. Gore S, Healey CJ, Sutton R, EyreBrook IA, Gear MWL, Shepherd NA, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-8.
45. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995;9:451-4.
46. Castell DO. Total acid suppression and its effect on Barrett's oesophagus. Am J Manag Care 2000;6(Suppl.16):S859-8.
47. Sampliner RE, Fass R. Partial regression of Barrett's oesophagus - an inadequate point. Am J Gastroenterol 1993;88:2092-4.
48. Sampliner RE. Effect up to 3 years of high-dose lansoprazole on Barrett's oesophagus. Am J Gastroenterol 1994;89:1844-8.
49. Ortiz A, Martinez De Haro LF, Parrilla P, Morales G, Molina J, Bermejo J, et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long term results of a prospective study. Br J Surg 1996;83:274-8.
50. Sagar PM, Ackroyd R, Hosie KB, Patterson JE, Stoddard CJ, Kingsnorth AN. Regression and progression of Barrett's oesophagus after antireflux surgery. Br J Surg 1995;82:806-10.
51. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's oesophagus in 67 patients. Dig Dis Sci 1990;35:93-6.
52. Williamson WA, Ellis FH, Gibb SP, Shahia DM, Aretz HT. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990;49:537-42.
53. Ertan A, Zimmerman M, Younes M. Esophageal adenocarcinoma associated with Barrett's oesophagus: long term management with laser ablation. Am J Gastroenterol 1995;90:2201-3.
54. Berenson MM, Johnson TD, Markowitz NR, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 1993;104:1686-91.
55. Luman W, Lessels AM, Palmer KR. Failure of Nd:YAG photocoagulation therapy as treatment for Barrett's oesophagus. Eur J Gastroenterol Hepatol 1996;8:627-30.
56. McBride MA, Vanagunas AA, Breshnahan JP, Barch DB. Combined endoscopic thermal electrocoagulation with high dose omeprazole therapy in complicated heterotropic gastric mucosa of the oesophagus. Am J Gastroenterol 1995;90:2029-31.
57. Barham CP, Shepherd N, Barr H. Regression of Barrett's epithelium using Agron Gas coagulation and acid supression. Gut 1996;39(Suppl 1):A29.
58. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000;46:574-7.
59. Kelly DJ, Shah JP. Management of Barrett's oesophagus. Lancet 1996;348:561-2.
60. Wooten RS, Ahlquist DA, Anderson RE, Carpenter HA, Pemberton JH, Cortese DA, et al. Localisation of hematoporphyrin derivative to human colorectal cancer. Cancer 1989;64:1569-76.
61. Laukka MA, Wang KK. Initial results using low-dose photodynamic therapy in the treatment of Barrett's oesophagus. Gastrointest Endosc 1995;42:59-63.
62. Overholt B, Panjehpour M, Tefftellar E, Rose M. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's oesophagus. Gastrointest Endosc 1993;39:73-6.
63. Barr H, Shepherd NA, Dix A, Roberts SJH, Tan WC, Krasner N. Eradication of high grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584-5.
64. Lord RV, Danenberg KD, Danenberg PV. Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinoma, and esophageal SCC: ready for clinical trials. Am J Gastroenterol 1999;94:2313-5.